AREDS2 Supplements: Who Actually Needs Them?

Walk down the supplement aisle and you will find a shelf of bottles with eyes on the label. Most of them are selling you an association: lutein is found in the macula, therefore lutein in a capsule must be good for the macula. The reasoning is not crazy, and it is also not evidence.

AREDS2 is the exception, and it is worth understanding precisely, because the precision is the whole point.

AREDS2 is a trial, not a brand

This trips people up constantly. AREDS stands for the Age-Related Eye Disease Study, run by the US National Eye Institute. AREDS2 was its successor, and it finished in 2013. What both produced was a formulation: a specific combination of nutrients at specific amounts, tested against placebo in thousands of people over years.

Any manufacturer can put that combination in a bottle and label it AREDS2. Some do it accurately. Others sell something adjacent, at a different composition, with the letters on the front. If you are going to take it, the composition is the product, and it is worth checking the panel against what was actually tested rather than trusting the name.

Who it actually helps

The trials enrolled people across a range of disease stages, and the result splits sharply along that range.

In the group where it works, the numbers are meaningful rather than dramatic. Around a quarter fewer people progressed to advanced AMD. In the original AREDS trial the risk of losing central vision fell by about 19% in the same group. Ten years after enrolment, participants originally assigned the antioxidant and zinc formulation were still 25 to 30% less likely to have developed advanced disease than those on placebo.

Read that carefully, because the wording carries the meaning. It slows progression in eyes that are already changing. It does not restore vision that has gone, it does not sharpen the vision you have, and it does not stop AMD from starting in an eye that does not have it.

Who it does nothing for, which is most buyers

The National Eye Institute is unambiguous on this point: the supplements showed no significant benefit for people with very early AMD, and none for people with no signs of the disease at all.

That covers most of the people currently buying it. Someone in their fifties who has noticed reading getting harder, whose mother had macular degeneration, and who wants to do something sensible. The instinct is good. The purchase is aimed at the wrong stage.

Why the formula changed, and why it matters

There is a genuinely useful story in how AREDS2 came to exist, and it explains why nutrient supplements deserve the same scrutiny as drugs.

The original AREDS formula contained beta-carotene. Beta-carotene is a vitamin A precursor, it is abundant in carrots and sweet potato, and in food it is entirely unremarkable. At supplement doses it turned out not to be. Large trials in smokers found that high-dose beta-carotene increased the risk of lung cancer rather than lowering it, which was the opposite of what everyone had expected.

AREDS2 was designed partly to fix that. It swapped beta-carotene for lutein and zeaxanthin, the two pigments the macula actually concentrates, and found the replacement was at least as effective and safer. That is why the current formulation looks the way it does.

The lesson generalises well beyond eyes. A nutrient that is beneficial in a carrot is not automatically beneficial in a capsule, and dose changes the answer. Anyone who still has an old AREDS formulation with beta-carotene in the cupboard, particularly a current or former smoker, should raise it with a professional rather than finishing the bottle.

What is in it, and why the amounts look high

The tested formulation is vitamin C, vitamin E, lutein, zeaxanthin, zinc, and a small amount of copper. The copper is not an afterthought. High-dose zinc interferes with copper absorption over time, so copper is in there to prevent a deficiency the zinc would otherwise cause.

The amounts are well above what you would get from food, and deliberately so: this was designed as a pharmacological intervention that happens to be built from nutrients. That is also why it is not a good idea to improvise your own version from separate bottles, or to stack it on top of a multivitamin without telling anyone. Zinc at these levels has interactions worth knowing about.

How to find out which group you are in

You cannot work this out from how your vision feels. Intermediate AMD is usually symptomless. What defines it is what an examiner sees at the back of your eye, chiefly the size and number of drusen, the yellowish deposits that accumulate under the retina, plus any pigment changes.

That means a dilated eye exam, and it means asking a direct question: do I have drusen, and if so, what stage would you call this? An optometrist or ophthalmologist can answer it in a sentence. It is a far better use of a hundred pounds or dollars than a year of capsules bought on a hunch.

If the answer is that you have intermediate AMD, AREDS2 becomes a reasonable conversation. If the answer is that your retina looks healthy, you have just been told the supplement would do nothing for you, which is worth knowing and is genuinely good news.

If you are not in the group, this is what is left

Not much of a supplement answer, and quite a lot of an everything-else answer. The habits with real evidence behind them for long-term macular health are unglamorous and mostly free: leafy greens and oily fish in the actual diet, not smoking, keeping blood pressure and blood sugar controlled, UV protection outdoors, and turning up for exams.

We have written the longer version of that as a complete guide to protecting your vision as you age. None of it is exciting. All of it has more behind it than a bottle bought on the strength of a picture of an eye.